UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 557

Sortiert nach

Signaling pathways essential for triple‐negative breast cancer stem‐like cells

Stem cells (Dayton, Ohio), 2021-02, Vol.39 (2), p.133-143

2021

Volltextzugriff (PDF)

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer

International journal of molecular sciences, 2023-02, Vol.24 (5), p.4522

2023

Volltextzugriff (PDF)

Increased Cholesterol Biosynthesis Is a Key Characteristic of Breast Cancer Stem Cells Influencing Patient Outcome

Cell reports (Cambridge), 2019-06, Vol.27 (13), p.3927-3938.e6

2019

Volltextzugriff (PDF)

Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy

Nature communications, 2022-07, Vol.13 (1), p.4118-4118, Article 4118

2022

Volltextzugriff (PDF)

HMGA2 as a Critical Regulator in Cancer Development

Genes, 2021-02, Vol.12 (2), p.269

2021

Volltextzugriff (PDF)

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Nature communications, 2017-09, Vol.8 (1), p.410-14, Article 410

2017

Volltextzugriff (PDF)

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

JNCI : Journal of the National Cancer Institute, 2017-09, Vol.109 (9)

2017

Volltextzugriff (PDF)

Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence

Nature medicine, 2017-11, Vol.23 (11), p.1319-1330

2017

Volltextzugriff (PDF)

Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer

International journal of molecular sciences, 2022-09, Vol.23 (17), p.10053

2022

Volltextzugriff (PDF)

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Nature communications, 2021-08, Vol.12 (1), p.5112-5112, Article 5112

2021

Volltextzugriff (PDF)

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

Nature communications, 2020-11, Vol.11 (1), p.5878-5878, Article 5878

2020

Volltextzugriff (PDF)

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer

Breast cancer research : BCR, 2018-06, Vol.20 (1), p.60-60, Article 60

2018

Volltextzugriff (PDF)

Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells

The Journal of immunology (1950), 2013-10, Vol.191 (8), p.4165-4173

2013

Volltextzugriff (PDF)

Plasma Membrane Proteomics and Its Application in Clinical Cancer Biomarker Discovery

Molecular & cellular proteomics, 2010-07, Vol.9 (7), p.1369-1382

2010

Volltextzugriff (PDF)

Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study

PloS one, 2012-05, Vol.7 (5), p.e36170-e36170

2012

Volltextzugriff (PDF)

Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study

Molecular oncology, 2014-07, Vol.8 (5), p.874-883

2014

Volltextzugriff (PDF)

KeyPathwayMinerWeb: online multi-omics network enrichment

Nucleic acids research, 2016-07, Vol.44 (W1), p.W98

2016

Volltextzugriff (PDF)

DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma

Molecular cancer, 2021-08, Vol.20 (1), p.108-108, Article 108

2021

Volltextzugriff (PDF)

PDX Models: A Versatile Tool for Studying the Role of Myeloid-Derived Suppressor Cells in Breast Cancer

Cancers, 2022-12, Vol.14 (24), p.6153

2022

Volltextzugriff (PDF)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Breast cancer research : BCR, 2021-02, Vol.23 (1), p.26-18, Article 26

2021

Volltextzugriff (PDF)

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer

Molecular oncology, 2018-06, Vol.12 (6), p.925-935

2018

Volltextzugriff (PDF)

Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors

Cell death & disease, 2020-02, Vol.11 (2), p.110-110, Article 110

2020

Volltextzugriff (PDF)

Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells

Nature communications, 2018-03, Vol.9 (1), p.785-12, Article 785

2018

Volltextzugriff (PDF)

Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis

Molecular cancer, 2024-01, Vol.23 (1), p.6-6, Article 6

2024

Volltextzugriff (PDF)

Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes

Molecular oncology, 2021-12, Vol.15 (12), p.3299-3316

2021

Volltextzugriff (PDF)

1 – 25 von 557

Suche als RSS-Feed

Aktive Filter

SprachePortugiesisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(429)
Mit Volltextzugriff
(396)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Signaling pathways essential for triple‐negative breast cancer stem‐like cells

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer

Increased Cholesterol Biosynthesis Is a Key Characteristic of Breast Cancer Stem Cells Influencing Patient Outcome

Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy

HMGA2 as a Critical Regulator in Cancer Development

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence

Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer

Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells

Plasma Membrane Proteomics and Its Application in Clinical Cancer Biomarker Discovery

Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study

Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study

KeyPathwayMinerWeb: online multi-omics network enrichment

DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma

PDX Models: A Versatile Tool for Studying the Role of Myeloid-Derived Suppressor Cells in Breast Cancer

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer

Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors

Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells

Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis

Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes

Aktive Filter

Suchergebnisse filtern